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ABSTRACT 
Lung cancer (LC) is one of the most common human cancers and the leading cause of 
cancer-related deaths worldwide. Treatment of LC is by surgery if the tumor is 
resectable, otherwise chemo- and/or radiotherapy (CT/RT) is given. However, 
development of resistance to CT/RT is very common which makes the prognosis of LC 
very poor with median overall survival of only about one year. This calls for discovery 
of novel diagnostic and/or therapeutic modalities. Biomarkers predicting response of 
LC to conventional CT have been identified based on some signaling alterations for a 
subset of NSCLC patients. The molecular aberrations for the rest of LC remain largely 
unclear. The main aims of this thesis were to investigate the potential of miRNAs as 
novel prognostic or therapeutic biomarkers of LC and to understand if some miRNAs 
could drive RT resistance.  
In Paper I we found that miRNAs are widely expressed in LC cell lines and we found 
a link between miRNA expression and RT sensitivity. We reported that miRNA-214 
and miRNA-324-5p are exclusively higher expressed in the radioresistant non-small 
and small cell lung cancer (NSCLC and SCLC) cell lines, respectively, as compared to 
the radiosensitive counterparts. Interestingly, we found that ablation of miRNA-214 in 
the NSCLC cells reversed RT resistance and induced senescence concomitant with up 
regulation of p27
Kip1
. In line with this, we observed that overexpression of miRNA-214 
in RT sensitive NSCLC cells blocked caspase-3-mediated apoptosis concomitant with 
activation of p38MAPK and phosphorylation of FoxO4. In conclusion we show that 
miRNA-214 confers resistance of NSCLC to RT.  
In Paper II we showed that miRNA-214 is modulating invasiveness of NSCLC cells. 
We demonstrated that ablation of miRNA-214 enhanced while overexpression of the 
miRNA reduced invasiveness of NSCLC cells. Through gene expression and 
bioinformatics analyses, we found that 18 genes out of the predicted miRNA-214 
targets were regulated in the NSCLC cells. Among these, we focused on four genes, 
PAPP-A, ALPK2, CDK6 and TNFAIP3, which were previously reported to be 
regulating metastasis in a mouse lung cancer model. Through argonaute 2 (Ago2) 
immunoprecipitation, we found that only ALPK2 is directly regulated by miRNA-214 
whereas PAPP-A, CDK6 and TNFAIP3 are indirect targets of this miRNA. Moreover, 
we performed immunohistochemical analysis of these targets in tissue microarrays of 
about 600 NSCLC tumors to reveal their expression pattern and to examine if a 
correlation could be made to metastatic potential of the tumors or overall survival (OS) 
of the patients. We showed that NSCLC tumors express these proteins at a moderate to 
high level although with no correlation to OS or clinical records of metastasis. In 
summary, we demonstrate that miRNA-214 regulates invasiveness of NSCLC yet 
further studies are required to delineate the molecular components involved.  
In Paper III the aim was to find biomarkers of cisplatin resistance in NSCLC cells. We 
showed that long-term NSCLC clones surviving cisplatin treatment had a 
heterogeneous gene expression pattern. We found DKK1, XRCC2 and LGALS9 to be 
linked to cisplatin resistance of NSCLC cells. Accordingly, we showed that knockdown 
of DKK1 sensitized NSCLC cells to cisplatin. Through Ingenuity pathway analysis we 
identified TCF4, EZH2, DNAJB6 and HDAC2 as altered upstream regulators of DKK1 
and GSK3B as a possible downstream signaling molecule. Further work is required to 
demonstrate their signaling role in cisplatin resistance of NSCLC cells.   
In summary, we show in this thesis that genomics techniques in combination with 
bioinformatics can be used to identify biomarkers of LC which could be used for 
prediction of prognosis or treatment response but also to reveal novel RT or CT 
sensitizing targets.  
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1 INTRODUCTION  
1.1 Lung cancer 
1.1.1 Clinical background  
Lung cancer (LC) is among the most frequent diagnosed cancers and the leading cause 
of cancer-related deaths worldwide. It is estimated that about 1.6 million new cases are 
diagnosed leading to about 1.38 million deaths each year which accounts for 18.2% of 
all cancer-related deaths worldwide [1]. LC is of two main histological subtypes which 
are non-small and small cell lung cancer (NSCLC and SCLC, respectively). The 
cornerstone of treatment for LC is surgery for localized disease; however, the majority 
of the cases are diagnosed at more advanced stages for which chemo- and/or 
radiotherapy (CT and RT, respectively) are the main curative treatment options. 
Despite the advances in diagnostic and surgical techniques and development of new RT 
and CT options, the prognosis of LC is still poor. Thus conventional CT and RT are 
effective in some, but most of the patients eventually develop resistance to treatment 
[2]. Using different approaches such as proteomics, metabolomics and genomics 
techniques to identify signaling networks of LC cells, certain of the molecular 
mechanisms underlying resistance to treatment have been revealed but still the overall 
picture is vague. To use a systems biology approach for analysis of signaling 
aberrations of tumor cells on a global scale has recently become feasible and shown 
great potential in identifying putative biomarkers of response and to find novel drug 
targets. In this thesis work, the genomic aspect of the systems biology, particularly 
miRNA and gene expressions in relation to RT and CT is under focus, with the aim of 
finding prognostic or therapeutic biomarkers for LC but also to identify novel RT/CT 
sensitizing targets.  
Histopathology 
Since many decades LC has been classified by pathologists into two main histological 
types, SCLC and NSCLC, with the latter accounting for about 85% of the cases and 
subdivided into adeno-, squamous cell- and large cell carcinoma (AC, SCC and LCC, 
respectively) [3]. However, after a multidisciplinary discussion including oncologists, 
radiologists, molecular biologists, surgical oncologists and pathologists, in which recent 
knowledge in molecular aberrations in LC were taken into consideration, the 
classification of LC has been updated [4]. It was thus agreed that pathologists should 
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make more distinct classification of LCs based on molecular investigations in small 
biopsies and cytologies which are possible to obtain from about 70% of the patients [3]. 
Previously, both AC and SCC were treated in a similar manner and a clear distinction 
was not of extra benefit, but nowadays, the practice has to be changed since certain 
therapies are effective against only a small subgroup of patients. For example, tyrosine 
kinase inhibitors like gefitinib or erlotinib and crizotinib, are recommended only for 
tumors with epidermal growth factor receptor (EGFR) mutations and anaplastic 
lymphoma kinase (ALK) rearrangements, respectively [5-7]. Further details about these 
mutations and targeted therapies are presented below.  
Staging and prognosis 
Clinically, LC is divided into four stages depending on how advanced the disease is, 
according to the TNM staging system which takes tumor size, lymph node involvement 
and metastasis to distant organs into consideration [8]. According to the latest version 
of TNM (i.e. 7
th
 edition), both SCLC and NSCLC are classified into four stages with 
majority of NSCLC cases being of stage II and III and for SCLC, stage III and IV [9, 
10]. 
Prognosis of LC varies according to the histological subtype and the clinical stage of 
the disease; however, the 5-year survival rate even for patients with early stage disease 
is ranging within 30-60% indicating a poor prognosis of the disease [11]. SCLC is 
considered as a very aggressive disease and if left untreated, the median survival will be 
about 2-4 months [12] and the 5-year survival rate of about 6.1% [13]. NSCLC is 
considered less aggressive with the 5-year survival rate being 50% for stage IA, 43% 
for IB, 36% for IIA, 25% for IIB, and 19% for stage IIIA [14, 15]. 
Management  
Diagnosis of LC is often made at advanced stages of the disease since it has no 
characteristic clinical features and is typically presented in the form of general 
respiratory symptoms like dyspnoea, cough and hemoptysis or general non-specific 
symptoms like weight loss and fatigue [16]. The disease is suspected from the clinical 
features but definite diagnosis is usually made through histopathological examination 
of a tumor biopsy or bronchial brushing or washing. Imaging of the chest and the other 
parts of the body is mostly done to define the extent and the clinical stage of the 
disease.  
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The latest guidelines and recommendations for treatment of NSCLC have been 
proposed by the European Society of Medical Oncology (ESMO) and are used also in 
Sweden [17]. Treatment of early stages of NSCLC i.e. stages I and II is aimed to be 
curative and includes surgical removal of the tumor. However, if surgery is 
contraindicated for any reason or the patient refuses to get operated, then stereotactic 
body radiotherapy (SBRT) is an alternative with favorable survival benefit and toxicity 
[18, 19]. For stage II tumors, different doublets of CT should be used as adjuvant 
treatment, which consists mainly of cisplatin in combination with other CT agents such 
as gemcitabine and vinorelbine. For resectable stage III NSCLC, concurrent cisplatin-
based CT and RT is usually given after surgical resection of the tumor while for non 
resectable stage III tumors, the treatment of choice is combined cisplatin-based CT and 
RT up to 60 gray (Gy) in fractions [17]. However, for advanced stages of the disease, 
usually palliative therapy is given in order to relieve the symptoms and consists of CT 
for example cisplatin, gemcitabine or pemetrexed or targeted therapies such as EGFR- 
or ALK tyrosine kinase inhibitors (TKI)s [10]. The role of palliative RT in advanced 
stage NSCLC is mainly used to relieve the metastasis-related pain or to control 
bleeding or airway compressions [10].  
Management of SCLC is also dependent on the stage of the disease and follows the 
ESMO guidelines and recommendations [9]. The treatment of localized disease, with 
no lymph node involvement or metastasis, includes surgery followed by adjuvant CT or 
as an alternative concomitant chemo-radiotherapy is used. For SCLC tumors reaching 
the ipsilateral lymph nodes or pleura, the best treatment option is concomitant CT and 
RT while for more advanced stages of the disease the treatment is usually palliative in 
the form of CT. For those patients responding to the first line treatment, prophylactic 
cranial irradiation should be considered in order to prevent brain metastasis [9].  
In the last decade, our knowledge of some of the molecular aberrations driving NSCLC 
tumors has generated favorable therapeutic options with less undesirable side effects. 
Examples are TKI for tumors with mutated EGFR such as gefitinib and erlotinib or for 
tumors with ALK rearrangement like crizotinib [14]. However, with respect to EGFR 
ablative therapy the problem is that it is only effective against a small subgroup of 
NSCLC patients of AC subtype, who have mutated EGFR [14]. Moreover, the vast 
majority of the cases recur because of development of resistance towards the EGFR 
TKIs and for this patient cohort no optimal treatment regimen is at hand. Therefore, 
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development of new drugs which can target a larger group of LC patients with tumors 
of different histological subtypes and molecular aberrations is urgently needed.   
1.1.2 Molecular aberrations in lung cancer 
With the complete sequencing of the whole human genome and the development of 
high throughput technologies, our understating of the molecular aberrations in LC that 
drive the processes of tumor development, progression, vascularization, invasion and 
the mechanisms of drug-induced cell death has improved. Focus of the scientific 
community in the last decade has thus been on applying these advanced techniques i.e. 
DNA sequencing, gene and miRNA analyses and mass spectrometry based proteomics 
to identify diagnostic, prognostic or therapeutic biomarkers or to discover targets that 
can be used for development of novel therapy. Certain of these molecular markers and 
their clinical applications in terms of LC will be explained below.  
 
In a large study of lung AC, DNA sequencing has demonstrated that certain genes are 
more frequently mutated for example EGFR, KRAS and EPHA3 (ephrin receptor A3) 
[20]. Similarly, analysis of lung SCC showed frequent amplification of SOX2 and 
FGFR1 and mutation of DDR2 [21-23]. In the squamous subtype of NSCLC, 
aberrations of immunological checkpoint proteins such as programmed death-1 (PD-1) 
have been identified more frequently than in other subtypes and monoclonal antibodies 
have been developed to target these proteins with promising results [24, 25].   
Certain molecular prognostic biomarkers have been identified for NSCLC and include 
oncogenes like KRAS, tumor suppressor genes such as p53 and DNA repair genes like 
excision repair cross-complementing group 1 gene (ERCC1) and ribonucleotide 
reductase subunit M1 (RRM1) [26-30]. KRAS mutations are frequently detected in 
NSCLC and found in about 25% of all such cases [26, 28]. A number of studies have 
shown a poor survival of NSCLC patients with KRAS mutation [27]. However in a 
multicenter study, mutations of p53 and KRAS were not associated with prognosis of 
NSCLC [31]. Thus, the predictive value of KRAS mutation in NSCLC needs to be 
further investigated. ERCC1 is involved in the nucleotide excision repair (NER)-
mediated repair of DNA strand breaks such as those induced by CT and other DNA 
damaging agents. Studies have shown that NSCLC patients with higher tumor 
expression level of ERCC1 (mRNA or protein) have longer survival rate than patients 
with low ERCC1 level [29, 30]. The prognostic significance of RRM1, another DNA 
repair protein which is involved in DNA synthesis, has also been shown in clinical 
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trials [32]. Thus a higher tumor expression of RRM1 was associated with higher 
survival rates of NSCLC patients as compared with those having lower RRM1 
expression [32, 33].   
Regarding the new therapeutic drugs developed based on known underlying targets, 
two groups of drugs have so far been introduced into the market; these are TKIs against 
EGFR mutation and ALK rearrangement [5-7]. EGFR TKIs like gefitinib and erlotinib 
have been shown to be highly effective mainly against lung AC with mutated EGFR 
being associated with longer progression free survival (PFS) as compared to 
conventional CT [6, 34]. On the other hand, those patients having a wild type EGFR 
had longer PFS in the CT-treated arm as compared to the gefitinib arm [34]. Certain 
less common genetic aberrations have recently been explored for therapeutic purposes 
in NSCLC such as BRAF mutation and c-MET amplification [35, 36]. Mutations in 
BRAF, which is a kinase downstream of KRAS, are most common in melanoma and 
this tumor has shown good response to BRAF-based TKI like vemurafenib [37]. 
Interestingly, in vivo LC mouse model studies have shown promising results in tumors 
bearing BRAF mutation treated with vemurafenib [35]. However, random selection of 
NSCLC patients for treatment with sorafenib, a multikinase inhibitor targeting among 
others, BRAF [38], was not associated with improvement of overall survival (OS) 
neither as single treatment nor in combination with CT [39, 40]. Other targetable 
genetic aberrations in NSCLC include MET amplification, a receptor tyrosine kinase, 
which enhances phosphatidylinositol 3-kinase (PI3K) signaling upon activation. MET 
amplification has been observed in 2-20% of lung ACs [41, 42]. Besides that, 
development of resistance to gefitinib has partly been attributed to MET amplification 
[43]. A number of kinase inhibitors and monoclonal antibodies have been developed to 
target MET amplification in preclinical and clinical studies with promising results [36]. 
However, standardization of the detection methods and optimization of patient 
selection is needed.  
Among the molecular markers being associated with response of NSCLC cells to CT 
are ERCC1 and RRM1 [30, 44]. It has been shown that NSCLC patients with stage I-
III tumors treated with adjuvant CT (cisplatin) had prolonged survival if their tumors 
were ERCC1 negative as compared to the control group while in ERCC1 positive 
tumors, there was no significant difference between the CT and the control arm [30]. 
Similarly, low tumor expression of RRM1 mRNA has been shown to be associated 
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with higher response rate of NSCLC patients to gemcitabine as compared to high 
RRM1 expression [44].  
1.2 MicroRNAs as potential biomarkers in lung cancer 
1.2.1 Background  
MicroRNAs (miRNAs, miRs) are endogenously expressed short single-stranded RNA 
molecules that negatively regulate gene expression. miRNAs regulate gene expression 
through either degrading the target mRNA or inhibiting translation of the mRNA into 
protein [45, 46]. The processing of miRNA is shown in Figure 1. First, miRNAs are 
transcribed from the genome by RNA polymerases in the form of long double stranded 
primary transcripts called pri-miRNA [47]. These transcripts are processed in the 
nucleus by a ribonuclease, Drosha, into shorter transcripts called precursor miRNAs 
(pre-miRNAs) [48]. Through the help of a transporter protein, Exportin-5, they are 
transferred to the cytoplasm [49] and then further processed through another 
ribonuclease, Dicer, which cleaves the pre-miRNA into 18-25 nucleotide long miRNA 
duplexes [50]. One of the strands of the duplex which becomes the mature miRNA will 
be directed towards the target mRNA in the RNA-induced silencing complex (RISC) 
complex via the help of argonaute 2 (Ago2) and the other strand will be degraded [51].  
 
Figure 1. A simplified schematic overview of miRNA biogenesis.  
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1.2.2 Functions of miRNAs  
miRNAs are regulating gene expression negatively and it is estimated that up to 60% of 
protein coding genes are regulated by miRNAs [52]. miRNAs have been shown to play 
important roles in regulation of different physiologic conditions such as organ 
development for example high miRNA-17-92 cluster expression is essential during 
lung development, apoptosis and differentiation [53-55]. miRNAs have also been 
shown to be involved in certain pathologic conditions including tumor development 
and in this context might function as oncogenes, often called oncomiRs, in which they 
are regulating tumor suppressor genes or conversely they can function as tumor 
suppressors upon targeting oncogenes [56].  
The influence of miRNA on tumor development or progression could be due to either 
modifications in the miRNA expression levels or modification of interaction between 
miRNAs and their mRNA targets. An aberrant miRNA expression during tumor 
development can be due to difference in the overall miRNA expression profile [57], 
chromosomal rearrangements [58], defects in the miRNA biogenesis machinery [59], 
point mutations in miRNA coding genes [60] or defects in the transcriptional regulation 
of miRNAs [61]. For example, deletion in the 3’UTR of HMGA2, which is targeted by 
the miRNA, let-7, leads to failure of the latter to regulate the gene enhancing lung 
tumorigenesis [62]. Another aberration is single nucleotide polymorphism (SNP) in the 
target genes which alter miRNA binding as exemplified by mutation in the 3’UTR of 
KRAS which disables let-7 family members from regulating the gene in NSCLC [63].  
1.2.3 miRNAs and hallmarks of cancer  
miRNAs can regulate almost all hallmarks of tumor development which include 
sustaining proliferative capacity, irresponsiveness to apoptosis, evading suppressors of 
cell growth, enabling replicative immortality and inducing angiogenesis (Figure 2) 
[64]. For instance, miRNA-221/222 is targeting the cell cycle regulator, p27
Kip1 
and 
thus influencing cell growth [65]. Several miRNAs have been shown to regulate 
different components of both the intrinsic and the extrinsic pathways of apoptosis and 
thus either promote or inhibit tumor development (Figure 3). In the intrinsic pathway, 
Bcl-2 and Bim mRNAs have been shown to be targeted by miRNA-15a/16 and 
miRNA-17/92 cluster, respectively [66, 67]. The pro-apoptotic protein, Puma, has been 
shown to be targeted by miRNA-221/222 [68] which is also targeting p27
Kip1
 [65]. In 
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the extrinsic pathway, miRNA-21 has been shown to regulate the expression of FAS-L 
[69].  
 
Figure 2. Examples of miRNAs involved in regulation of hallmarks of cancer.  
 
With respect to sustained angiogenesis, miRNA-424 has been shown to enhance 
angiogenesis via up regulation of HIF-α1 and HIF-α2 [70]. miRNA-200 family has 
been shown to enhance invasion and metastasis in LC mouse models by regulating 
epithelial mesenchymal transition (EMT) [71]. Different components of the 
angiogenesis pathway have also been targeted by miRNAs. Thus, down regulation of 
miRNA-126, which is an endothelial cell-specific miRNA, has been associated with 
angiogenesis reduction through negative regulation of a component of VEGF pathway, 
SPRED1 [72]. Other miRNAs also have anti-angiogenic property such as miRNA-
15a/16 which target VEGF mRNA [73].  
Similarly, miRNAs have been shown to regulate different components involved in 
invasion and metastasis of tumor cells such as high miRNA-103/107 being associated 
with high invasiveness and metastasis of breast cancer via regulation of Dicer and 
miRNA-200 [74].  
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Figure 3. A simplified schematic outline of intrinsic and extrinsic apoptotic pathways. 
Some examples of miRNAs involved in regulation of these pathways are shown.  
 
1.2.4 miRNAs as diagnostic and prognostic biomarkers 
miRNAs can serve as new diagnostic tools and even for classification of tumor 
subtypes as illustrated by a list of 56 differentially expressed miRNAs in lung tumors as 
compared to normal lung tissue [75]. It is even possible to use non-invasive methods to 
detect the level of miRNAs in different body fluids including blood, plasma, serum, 
urine, saliva and amniotic fluid [76]. In the circulation, miRNAs are protected inside 
micro vesicles called exosomes which are secreted to the circulation from different cell 
types [77]. A number of studies have shown that miRNAs are differentially secreted 
into the serum or blood of LC patients [78, 79]. Using miRNA sequencing, it was thus 
shown that 76 miRNAs have a significantly higher level in serum of NSCLC patients 
as compared to healthy controls followed by q-RT-PCR validation of the highest 
expressed miRNAs i.e. miRNA-223 and miRNA-25 [78]. In another study, miRNA 
expression profiling in relation to OS of NSCLC patients, stage I-III AC and SCC, was 
tested using solexa sequencing [79]. It was found that miRNA-499, miRNA-1, 
miRNA-486 and miRNA-30d had a higher expression in patients with longer OS 
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(mean survival time 49.5 months) than those with shorter OS (mean survival time 9.5 
months) showing that circulating miRNAs can serve as prognostic biomarkers.   
Several studies have shown that miRNAs can be suitable prognostic biomarkers of 
tumors in general and of LC in particular. High expression of miRNA-146b and 
miRNA-155 in lung SCC and AC, respectively, was associated with poor OS of the 
patients after surgical resection of the tumor [80, 81]. miRNA expression profiling of 
formalin-fixed, paraffin-embedded (FFPE) NSCLC tumors of stage I-III has shown that 
miRNA-221, 137, 372, 182* and let-7a have prognostic value [82]. However, until till 
now their utility as clinical biomarkers has been hampered by the inconsistence of 
miRNAs revealed in the different studies. This can probably be explained by the fact 
that the miRNA-mRNA interacting network is more complex and that different factors 
can influence the downstream signaling pathways. Moreover usage of current 
techniques for analyzing miRNAs may also influence the results and generate 
inconsistent profiles.  
1.2.5 miRNAs as therapeutic targets 
Since miRNAs can function as oncogenes or tumor suppressors and are involved in the 
regulation of different cellular processes important for tumor cell survival and death, 
they are indeed suitable as therapeutic targets. In this respect, miRNAs have a number 
of advantages. First, miRNAs can reduce the concentration and not only the activity of 
the target oncogenic proteins as they can degrade the targets. Second, miRNAs can 
target multiple oncogenes simultaneously which might reduce the need for combination 
therapies.  
Drugs based on targeting miRNAs can be used in the form of replacement therapy such 
as mimics of miRNAs which can minimize the effect of certain oncogenes. A good 
example of miRNA replacement therapy is the intra-tumoral introduction of the 
miRNA, let-7, into mouse models of NSCLC which reduced the tumor size [83]. 
Antagonists of miRNAs can also be used to reduce the tumor expression level of 
oncogenic miRNAs and in turn increasing the level of specific tumor suppressor genes. 
One such example was the use of miRNA-21 antagonists in glioma cell lines which 
activated caspase-induced apoptotic pathway [84]. Another approach to introduce 
miRNAs into the therapeutic field is called indirect miRNA-based therapy. As some 
tumors have a low level of certain miRNAs as compared to normal cells, thus 
introducing vectors which carry miRNA-regulated suicide genes into the tumor cells 
may lead to high abundance of the suicide gene in the cancer cells not in the normal 
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cells. Albeit these therapies are promising in preclinical and animal settings, further 
refinement of vehicles or administration routes are required to enable entrance to the 
clinical practice.  
1.2.6 miRNAs as regulators of radiotherapy response  
Radiotherapy (RT) is one of the main curative therapeutic options of both SCLC and 
NSCLC patients with locally advanced disease [9, 17]. The principal signaling of 
ionizing radiation involves triggering of different types of DNA damages of which 
DNA double strand break (DSB)s are the most critical. These are formed either through 
indirect ionizations within the DNA but more important through the formation of free 
radicals. In response to these DNA damages certain major cellular response pathways 
are started which include the DNA damage detection response (DDR), DNA damage 
repair systems, cell cycle regulating networks and different cell death signaling 
cascades including apoptosis (Figure 4). Accordingly, putative biomarkers of RT 
responsiveness as well as RT sensitizing strategies may be found among all these 
pathways but so far no biomarker has clinically been established for such purpose. 
Given that miRNAs may interfere with tumor signaling at multiple levels, it is not 
surprising that they also impact on RT response of tumors. It has thus been shown that 
miRNAs can regulate several genes involved in various steps of RT signaling. For 
example, the influence of lin-28/let-7 expression on RT sensitivity was tested in 
NSCLC cell lines with mutated KRAS and wild type KRAS. It was shown that 
overexpression of let-7a or down regulation of lin-28, a repressor of let-7, led to down 
regulation of KRAS and sensitized the cells to RT in KRAS mutated but not KRAS 
wild type cells [85]. In another study, high level of let-7g and miRNA-9 was associated 
with enhanced sensitivity of NSCLC cell lines to gamma irradiation through negative 
regulation of NFқB1 [86]. It was also shown that NSCLC cell lines with different 
response to RT had different miRNA expression pattern and that miRNA-449a was 
down regulated in the radioresistant subset of cell lines. Further, overexpression of the 
miRNA-449a sensitized the RT refractory NSCLC cells to IR through enhancing DNA 
damage, cell cycle arrest and apoptosis [87]. The role of miRNA-210 in RT response 
has been shown in NSCLC cell lines, where it was found that high levels of the miRNA 
in hypoxic conditions enhances radioresistance through induction of hypoxia-induced 
factor 1 (HIF-1) [88]. miRNA-101 has also been shown to enhance radiosensitivity of 
most of the NSCLC cell lines after ectopic expression through targeting the DDR 
protein, ataxia telangectasia mutated (ATM), and the non homologous end joining 
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(NHEJ) repair protein, DNA-PKcs; however, it failed to do so in some other cell lines 
with high endogenous level of the miRNA-101 and even in xenograft models [89]. In 
another in vitro study, the importance of high levels of miRNA-155 and 20a in IR-
induced senescence was shown in lung fibroblasts and for miRNA-155, the 
downstream signaling pathway was shown to be p38 mitogen-activated protein kinase 
(p38MAPK) [90].  
 
Figure 4. A diagrammatic overview of IR-induced DNA damage induction and cellular 
response.  
 
Apart from regulation of the different steps induced by IR, several miRNAs have been 
linked to the sensitivity or resistance of LC, both in vitro and in vivo [85-94]. High 
expression level of certain miRNAs through targeting different pathways were shown 
to be associated with enhanced sensitivity of LC cells to IR such as let-7a [85], let-7g 
and miRNA-9 [86], miRNA-449a [87], miRNA-34b [93] and miRNA-101 [89]. On the 
other hand, low level of certain miRNAs was shown to be associated with better 
response to IR in normal lung fibroblasts for example miRNA-210 [88] or in LC cell 
lines such as miRNA-155 [90]. However, the direct downstream targets of these 
miRNAs were not identified. 
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Among the in vivo studies, Lussier and colleagues have shown that NSCLC patients 
with oligometastasis (i.e. ≤ 5 metastatic sites) have a different miRNA expression 
pattern compared to those who develop polymetastasis (i.e. > 5 metastatic sites) and 
thus have a poorer chance of response to SBRT. These oligometastatic NSCLC tumors 
were found to express higher level of miRNA-200 family members [91]. miRNA 
expression patterns have also been used  to classify NSCLC patients into radio-
sensitive (RS) and radio-resistant (RR) groups and a 12-miRNA signature was revealed 
[92]. Five of the miRNAs (miRNA-126, let-7a, 495, 451 and 128b) were up regulated 
and the remaining seven miRNAs (miRNA-130a, 106b, 19b, 22, 15b, 17-5p and 21) 
were down regulated in the RS group [92]. The role of miRNA-126, the most up 
regulated miRNA, in modulating RT sensitivity was further shown in vitro to be 
modulating PI3K-Akt pathway illustrating that this miRNA has the potential to be used 
as a therapeutic target [92].  
1.3 Chemotherapy 
Different principal groups of CT agents with different mechanism of action are used in 
LC therapy and these include alkylating agents, microtubule targeting agents, DNA 
synthesis inhibitors and topoisomerase inhibitors. However, the DNA crosslinking 
platinum compounds are the most widely used ones usually in combination with 
another drug. Out of these platinum-containing  compounds, cisplatin is the most well-
known and the most frequently used one for treatment of many solid tumors, including 
LC, being first approved by the FDA for the treatment of testicular- and bladder cancer 
in 1978 [95]. However, development of serious side effects such as bone marrow 
suppression and neuro- and nephrotoxicity, and development of resistance to the 
treatment forced the development of two other derivatives of platinum compounds, 
carboplatin and oxaliplatin. Carboplatin was first approved by FDA in 1989 for the 
treatment of ovarian cancer [96] and oxaliplatin in 2002 for treatment of colorectal 
cancer [97]. These two compounds have less serious side effects but still the major 
obstacle in using these drugs is the development of therapy resistance as they have 
similar chemical structure as cisplatin. However, in a number of clinical trials, it was 
shown that doublets composed of cisplatin with different other CT agents had better 
therapeutic potential in terms of OS when compared to carboplatin or oxaliplatin [17]. 
Therefore, cisplatin combined with etoposide or vinorelbine is still the recommended 
doublet for LC treatment. 
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1.3.1 Mechanism of action of platinum compounds   
Cisplatin as well as the structurally related compounds, carboplatin and oxaliplatin, 
mediate antitumor effects via binding to the DNA helix, forming intra- and inter-strand 
crosslinks thereby inducing DNA single and double strand breaks (SSB and DSB, 
respectively) [98]. The consequence of these DNA adducts is dependent on the extent 
of DNA damage which dictates either a DNA damage repair response of the tumor cell 
and thus survival of the tumor cells or leads to activation of cell death signaling 
networks including apoptosis [99]. Thus, if the amount of DNA damage is less 
extensive, the cells will be arrested at S and G2/M phase of cell cycle and the DNA 
repair machinery will be activated, allowing cell survival [99]. However, if the DNA 
damage is extensive, apoptotic cell death will occur as a result of cytochrome c release 
from the mitochondria followed by activation of procaspase-9 and then caspase-3 and 
subsequently cell demise (Figure 3) [99]. Accordingly, a number of proteins are 
activated in response to DNA damage and mediate the downstream signaling pathways 
involved in cell cycle arrest, DNA repair and apoptosis. Hence platinum-induced 
formation of inter- and intra-strand adducts in DNA will recruit sensors of DNA 
damage which in turn activates components of DNA repair machinery. The most 
commonly recognized DNA repair pathways for platinum compounds are nucleotide 
excision repair (NER), mismatch repair (MMR), homologous recombination (HR) and 
non-homologous end joining (NHEJ) repair (Figure 5) [100].   
 
Figure 5. A schematic overview of principal DNA repair pathways induced upon 
treatment with cisplatin.  
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1.3.2 Role of miRNAs in chemotherapy response 
Several studies have shown that miRNAs can regulate the response of LC cells to 
cisplatin, gemcitabine, paclitaxel and docetaxe, the most clinically used CT agents for 
LC [101-115]. Among the miRNAs regulating response of LC cells to cisplatin is 
miRNA-98 which inhibits p53 and enhances up regulation of Blc-2 causing drug 
resistance [101]. On the other hand, overexpression of miRNA-497 through down 
regulating Bcl-2 [102] and miRNA-451 possibly via targeting Akt signaling pathway 
has been shown to sensitize NSCLC cells to cisplatin [103]. In another study, it was 
demonstrated that up regulation of miRNA-181a and down regulation of miRNA-630 
enhanced cisplatin-induced cell death in NSCLC cell lines [104]. Moreover, 
overexpression of miRNA-200bc/429 was also demonstrated to sensitize NSCLC cells 
to cisplatin by targeting Bcl-2 and XIAP [106].  
Among the miRNAs regulating response of LC cells to paclitaxel, which is used as a 
first line treatment of advanced NSCLC, is miRNA-135a which enhances resistance to 
the drug through down regulation of adenomatous polyposis coli (APC), in vitro and in 
vivo [109]. miRNA-101 has also been reported to sensitize  NSCLC cells to paclitaxel 
via targeting enhancer of zester homolog 2 (EzH2) and subsequently enhancing 
apoptosis as visualized by high Bim-2 expression and PARP cleavage [110].    
Certain miRNAs have been linked to response of LC to anthracyclins such as 
doxorubicin. In an in vitro study, it was shown that high expression levels of miRNA-
134, miRNA-379 and miRNA-495 increase the sensitivity of SCLC cells to 
doxorubicin [108]. It was also shown that miRNA-128-2 confers resistance of NSCLC 
cells to doxorubicin through negative regulation of the transcription factor, E2F5 [111], 
while miRNA-1 overexpression sensitized the cells to doxorubicin by increased 
caspase-3 and -7 mediated apoptotic signaling [112]. In relation to gemcitabine, low 
level of miRNA-133b, which regulates pro-survival proteins, myeloid cell leukemia 
sequence 1 (MCL-1) and BCL-2-like protein 2 (BCL2L2), has been shown to be 
associated with drug resistance [113]. The response of SCLC to etoposide has also been 
shown to be modulated by miRNA-134, miRNA-379 and miRNA-495 [108].  
In summary, the above mentioned studies indicate that miRNAs play an important role 
in the response of LC to CT through targeting different signaling pathways and in a cell 
dependent manner.  
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2 AIMS  
The overall aim of this thesis was to find novel biomarkers which can be used to predict 
the response of NSCLC to conventional chemo- or radiotherapy or be used as 
sensitizers of these conventional therapies. The specific aims of each project were:  
 
 To identify miRNAs which can be linked to RT response of NSCLC and 
SCLC (Paper I).  
 To analyze miRNA-214 targets and their significance for invasion and 
metastatic spread of NSCLC (Paper II).  
 To find novel cisplatin resistance mechanisms of NSCLC and determine 
pathways to be targeted for improvement of cisplatin response (Paper III).   
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3 MATERIALS AND METHODS   
3.1 Cell lines 
A panel of SCLC and NSCLC cell lines was used in this thesis. Their intrinsic 
radiotherapy sensitivity which has been tested through colony formation assay and 
measured as surviving fraction after two grays (SF2) are given in Table 1.  
 
Table.1 Histology and SF2 values of the cell lines used.  
 
Abbreviations: SF2: surviving fraction after 2-Gy irradiation, NSCLC: non-small cell 
lung cancer, SCLC: small cell lung cancer, AC: adenocarcinoma, SCC: squamous cell 
carcinoma, LCC: large cell carcinoma. 
3.2 Patient tumor material  
A cohort of 598 tumors obtained from NSCLC patients was used in Paper II for 
analysis of biomarker expression using immunohistochemistry (IHC) on tissue 
microarrays (TMA)s. The patients were operated for curative resection of the tumor at 
Karolinska University Hospital, Sweden during 1997-2004. The tumors were formalin-
Histology Cell line SF2 value References 
 A549 (AC) 0.62-0.82 [116, 117] 
 H23 (AC) 0.17-0.20 [116, 117] 
NSCLC H157 (LCC) 0.38-0.8 [116, 117] 
 H661 (LCC) 0.93 [116] 
 H1299 (AC) 0.3 [118] 
 U-1810 (LCC) 0.80-0.88 [119, 120] 
 H69 0.23-0.25 [116, 121] 
 H82 0.58-0.73 [116, 121] 
SCLC U-1285 0.25-0.30 [119, 120, 122] 
 U-1690 0.57 [123, 124] 
 U-1906 0.45-0.59 [119, 120] 
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fixed paraffin embedded (FFPE) and archived. Ethical permit for research usage of the 
material was taken from Karolinska Institutet ethical committee (2005/588-31/4). For 
details of the patient characteristics and the exclusion criteria of the samples in the 
study see Materials and methods section of Paper II.   
3.3 Treatments 
In this thesis two commonly used treatment options in NSCLC were applied which 
were IR (Co
60
 source) and cisplatin. In Paper I the aim was to study effect of radiation-
induced cell death and how that could be manipulated. A dose of 8-Gy IR was chosen 
as the NSCLC cell line used, U-1810, was previously shown to be refractory to this 
dose during a 72h period [125, 126]. For H23 cells also, 8 Gy was used in order to 
analyze the protective role of miRNA against induction of RT-induced cell death. For 
clonogenic survival in Paper III a range of cisplatin doses was applied (2.5-20 µM) 
whereas for gene expression profiling and the rest of experiments, 10 µM cisplatin was 
chosen. The doses applied in clonogenic survival assays are clinically relevant as these 
doses have been measured in plasma of cancer patients after cisplatin administration 
[127]. 
In Paper I and II, we used mimic and antagomir of miRNA-214 to increase or 
decrease the endogenous level of this miRNA in NSCLC cells, respectively, and 
thereafter study the effect on RT response and invasion capacity. Antagomir of miRNA 
is composed of RNA oligonucleotides with novel secondary structure which improves 
the efficacy and longevity of the molecule [128]. Antagomirs are used for loss-of-
function studies. Mimic of miRNA is a double-stranded oligonucleotide chemically 
enhanced to preferentially program RISC with active miRNA strand [129]. Mimics of 
miRNAs are used for gain-of-function studies.  
3.4 Cell death and survival assays 
Assessment of apoptotic nuclear morphology 
DAPI (4',6-diamidino-2-phenylindole), a fluorescent dye which can pass through intact 
cellular membrane and bind to the DNA, was used to stain the cellular nuclei after 
treatment with IR in order to detect apoptotic features of cell nuclei such as chromatin 
condensation and fragmentation (Paper I).   
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Analysis of cell cycle distribution and caspase-3 activity  
Flow cytometry is a broadly used technique to measure cellular DNA content in each 
phase of cell cycle and the fraction of cells with apoptosis [130]. This technique was 
used to measure the cell cycle progression and percentage of cells with sub-G1 (Paper 
I). In order to permeabilize the cell membrane, digitonin which facilitates entry of the 
stain into the cells, was applied. Propidium iodide (PI) which is a fluorescent dye was 
used to assess DNA content. The cells were fixed in ethanol and permeabilized by 
digitonin and then treated with RNase-A followed by staining with PI. To measure 
apoptotic signaling, a FITC-conjugated anti-caspase 3 antibody which recognizes 
active caspase-3 was applied in flow cytometry. The amount of fluorescence emitted 
from the stained cells was then captured by a flow cytometer and the percentage of 
cells for each phase of the cell cycle or stained with FITC-conjugated antibody was 
then revealed [130].  
Senescence assay  
Senescence is a cellular state recognized by inability of cells to divide which is 
associated with morphological changes and gene expression alteration. We used a 
commercially available kit to measure the activity of β-galactosidase enzyme, a marker 
of this phenotype (Paper I) [131].  
Colony formation assay 
Colony formation assay is a commonly used method to measure cytotoxicity of 
treatments such as CT or RT. It is based on the assessment of the capability of single 
cells to undergo cell division and form colonies over a period of 1-3 weeks [132]. The 
colonies are thereafter stained and the relative survival proportion to untreated cells is 
used to describe the cytotoxicity of treatment. We used this assay to measure the 
response of cells to cisplatin treatment and also isolated these clones for gene 
expression profiling (Paper III).   
3.5 Invasion assay  
Invasiveness of tumor cells is commonly measured via transwell invasion chambers in 
vitro. We used this technique to assess the invasiveness of NSCLC (Paper II). Because 
of the high invasive potential of the cells used, difficulties in accurate counting of the  
number of invading cells was experienced therefore another more recently established 
technique, real-time cell invasion and migration (RT-CIM) system [133], was applied. 
 20 
A special plate is used for this purpose which has electrodes attached to the under 
surface measuring the electrical impedance imparted by the invasive cells upon time. 
The advantage of this method over the transwell assay is that the invasiveness can be 
measured in real time as the electrodes are continuously attached to the plate and 
automatically registers the impedance as it is set up [134].   
3.6 MicroRNA and gene expression assays  
Microarray  
MicroRNA microarray is one of the broadly used techniques for assessment of miRNA 
expression but there are also other alternatives such as bead-based technology and RT-
PCR-based techniques [135]. In Paper I we applied microRNA microarray technology 
(Affymetrix Inc., Santa Clara, CA, USA) to profile miRNA expression in the NSCLC 
and SCLC cell lines panels on a global scale. We used this technique for miRNA 
profiling as it has the capacity of high-throughput profiling covering a large number of 
miRNAs and it is a golden standard technique in the field [136]. The total RNA from 
the cells was labeled with biotin and then hybridized onto the microarray chip. After 
washing and staining steps, the array chips were scanned using LASER scanner. The 
signal intensities for each probe were background extracted and normalized to the 
spike-in controls. For gene expression profiling in Paper II and Paper III the same 
technique was used but instead of miRNA probes, multiple transcript probes covering 
different lengths of about 22 000 genes were applied [137]. 
Quantitative real-time polymerase chain reaction (q-RT-PCR) 
 q-RT-PCR is a technique measuring the copy number of a gene of interest in the cells 
via its amplification and detection in real time [138]. The principle of the technique is 
based on ordinary polymerase chain reaction except for the fact that the end product of 
amplification is detected and quantified at the end of each reaction. The product used 
for this purpose is total RNA which is reverse transcribed to cDNA via a transcriptase 
enzyme and through the help of specific primers the gene of interest is amplified and 
detected. For q-RT-PCR analysis of miRNA expression, TaqMan miRNA primers and 
probes designed by Applied Biosystems were used [139]. This looped structure of the 
primer allows for more specific and efficient detection of the mature miRNAs. This 
technique was used in both Paper I and II for validation of the microarray findings 
and the efficiency of transfection with antagomirs or mimics of miRNA. For 
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amplification and quantification of other genes than miRNA, ordinary q-RT-PCR was 
applied (Paper I-III).  
3.7 Bioinformatics analyses   
We used a number of bioinformatics tools to analyze the miRNA and gene expression 
data. For prediction of miRNA targets, three commercially available softwares, 
Targetscan, PicTar and MicroCosm (previously called miRBase) were applied in order 
to find the targets of miRNA-214 in an unbiased way (Paper I). Each of these tools 
uses a different background algorithm to predict the targets of miRNAs [140-142]. 
PicTar predicts the targets of miRNAs based on sequence match between the seed 
region of 5´end of miRNAs and the 3´ UTR of the mRNAs [141]. TargetScan also uses 
the sequence match between the seed region of miRNA and the 3´ UTR of the mRNAs 
but also takes the conservation of miRNA targets between different species into 
consideration [142]. MicroCosm takes the sequence similarity and conservation across 
species into account for predicting the targets of miRNAs and finding multiple 
sequence matching across the 3´ UTR of the mRNAs and besides that it gives a P-value 
for each predicted target [140]. To integrate each gene of interest into signaling 
pathways and find relevant testable hypothesis, we used Ingenuity Pathway Analysis 
(IPA) tool (Paper I, II and III). IPA is one of the three most frequently used network 
analysis tools in systems biology field and is based on manual annotations about genes 
and proteins and thereby building networks of interactions [143]. In Paper II, another 
function of IPA called ingenuity miRNA target filter was applied to find the targets of 
miRNA-214. This tool is based on findings of Targetscan and Tarbase tool, the latter 
describes the experimentally proven targets of miRNAs [144], and Ingenuity 
intelligence center to identify the targets of miRNAs.  
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4 RESULTS AND DISCUSSION  
4.1 Paper I 
miRNA-214 modulates radiotherapy response of non-small cell lung cancer cells 
through regulation of p38MAPK, apoptosis and senescence 
In this study we aimed to understand if miRNA expression could be linked to RT 
responsiveness of LC and identify signaling events that could be targeted for RT 
sensitization purposes. For that purpose, we used a panel of SCLC and NSCLC cell 
lines with different intrinsic RT sensitivity (measured via colony formation assay and 
indicated by SF2 (Table 1). The outline of the study is shown in Figure 6.  
 
 
Figure 6. Schematic outline of experimental setup (Project I). RR and RS represent 
radioresistant and radiosensitive, respectively.  
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Through miRNA profiling, we showed that each LC cell line expressed about 100-200 
miRNAs at a level which was significantly over background. All the NSCLC cell lines 
had 69 miRNAs in common while the SCLC cell lines shared 56 miRNAs. The 
NSCLC cells differentially expressed 25 miRNAs compared to the SCLC cell lines 
which in turn differentially expressed 10 miRNAs.  
The cell lines were divided into two groups with a cutoff SF2 value of 0.3 to 
differentiate radioresistant (RR) cells (SF2 value ≥ 0.3) from the radiosensitive (RS) 
one (SF2 value < 0.3). With this approach, a number of miRNAs were found to be 
expressed in one or more of the RR NSCLC or SCLC cell lines and not in the RS ones 
as illustrated in (Figure 7).  
 
Figure 7. miRNAs differentially expressed in radioresistant (RR) and radiosensitive 
(RS) NSCLC and SCLC cell lines.  
 
 In the clinical setting, in general, SCLCs are known to be responsive to both CT and 
RT in the first line but majority of the patients develop resistance to treatment resulting 
in tumor progression and poor outcome [9]. Previous reports from our group have 
suggested that a RR phenotype of SCLC is in part attributed to defective apoptotic 
propensity possibly due to lack of components of apoptotic cascade e.g. pro-apoptotic 
caspase-8 and high Bcl-2/Bax ratio [145] but also as a consequence of increased DDR 
and DNA repair signaling [146]. Yet, the role of miRNAs in this context remains 
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elusive. In our study, we found miRNA-324-5p to have a differentially higher 
expression in the RR subtype of SCLC (Figure 7). Expression of this miRNA in other 
tumor types has been shown to be associated with tumor development and metastasis 
[147, 148]. Thus, overexpression of miRNA-324-5p was found to prevent 
medulloblastoma development via down regulation of the transcription factor, Gli1 
[147] and up regulation of miRNA-324-5p is reported to be associated with distant 
metastasis of oropharyngeal carcinoma [148]. However, the functional role of miRNA-
324-5p in SCLC and in their RT response has not been addressed. Interestingly, when 
analyzing the predicted targets of miRNA-324-5p, a number of proteins involved in 
apoptosis such as apoptotic peptidase activating factor 1 (Apaf-1), Diablo and calpain 
as well as DNA repair components like Rad52 and Runx1 were identified. Thus, 
alteration in miRNA-324-5p may explain the observed alteration in apoptosis and DNA 
repair in SCLC but further studies are required to prove if this is the case.   
In NSCLC, we found miRNA-21 among the miRNAs which were linked to 
radioresistance (Figure 7). Interestingly, miRNA-21 has previously been shown to 
have a lower expression in NSCLC tumors responding to postoperative RT as 
compared to poor responders indicating a potential role of this miRNA in 
radioresistance [92]. In vitro studies have also linked miRNA-21 to RT and both cell 
cycle check point proteins like CDC25A [149] and DNA repair proteins like mismatch 
repair (MMR), such as human mutS homolog 2 and 6 (hMSH2 and hMSH6, 
respectively) are influenced by this miRNA [150].  
One of the important findings of this study was that miRNA-214 was linked to a RT 
refractory phenotype of NSCLC. In order to substantiate a role for miRNA-214 in RT 
response, we used antagomirs towards this miRNA and could demonstrate that ablation 
of miRNA-214 expression in RR NSCLC sensitized for RT-induced senescence but not 
apoptosis. Moreover, through overexpression of miRNA-214 in a RT sensitive 
NSCLC, we observed decreased RT-induced apoptotic response (Figure 8). Thus, we 
proved that miRNA-214 is a regulator of RT response of NSCLC cells. The 
significance of miRNAs in regulating apoptotic pathways has been described 
previously such as negative effect of miRNA-17-5p on apoptosis via targeting the pro-
apoptotic protein, Bim [151], or miRNA-1 and miRNA-101 through targeting the anti-
apoptotic protein, Mcl-1 (Figure 3) [152]. However, modulation of different modes of 
cell death i.e. apoptosis and senescence in response to manipulation of miRNA-214 
may have different explanations. First, the cell type-specific effects of miRNAs cannot 
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be ignored as it has been shown in many studies that the same miRNA could target 
different pathways in different tumor types. For example miRNA-214 is influencing 
metastatic potential of malignant melanoma through regulating transcription factor AP2 
gamma (TFAP2C) while in cervical cancer via targeting plexin-B1 [153, 154]. Second, 
the higher magnitude of miRNA-214 overexpression after introducing mimic-214 in 
the RS cells which was even higher than the baseline level of the miRNA-214 in the 
RR cells could possibly influence other targets than just senescence. We observed 
increased senescence after miRNA-214 ablation in RT resistant NSCLC cells and in 
order to further analyze possible molecular determinants involved, we checked the 
expression level of two well-known cell cycle and senescence regulators, p21
WAF1/Cip1 
and p27
Kip1
 [155-157] using western blot. We observed no change in the p21
WAF1/Cip1 
expression in the RR NSCLC cells after miRNA-214 knockdown in combination with 
IR. One possible explanation could be that the primary transcriptional regulator of 
p21
WAF1/Cip1
, p53 [158], is mutated resulting in lack of its expression in these cells [159] 
which may cause this signaling circuit to  be impaired. Although senescence is mainly 
occurring during the G0 phase of the cell cycle, induction of senescence at G2/M arrest 
has also been reported in human tumor cells through a mechanism involving the anti-
apoptotic protein Bcl-XL inhibition of cyclin-dependent kinase 1 (CDK1) which is 
controlling G2/M phase of the cell cycle [160]. Such a mechanism is in line with our 
data as we found that miRNA-214 knockdown sensitizes the NSCLC cells to IR 
through G2 cell cycle arrest and induction of senescence with a concomitant increase in 
p27
Kip1
expression. A role of p27
Kip1
 in G2/M arrest has been reported in different 
studies [161, 162], further supporting this explanation. Hence elucidation of the 
downstream target of p27
Kip1
 involved in the G2/M arrest and induction of senescence 
in these NSCLC cells would therefore be interesting.  
To identify the potential targets of miRNA-214 which could govern a RR phenotype of 
the NSCLC cells in an unbiased way, we used three common miRNA target prediction 
tools, Target scan, PicTar and MicroCosm [141, 142]. The target genes in common 
were further investigated using IPA with respect to connection to apoptosis and/or 
senescence. One of the reported targets of miRNA-214 was phosphatase and tensin 
homolog (PTEN), a tumor suppressor which has previously been reported to confer RT 
sensitivity via inhibition  of the pro-survival PI3K/Akt signaling pathway [163, 164]. 
PTEN has been demonstrated in ovarian cancer cells and monocytes to be a direct 
target of miRNA-214 and in these cells, ablation of miRNA-214 expression was found 
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to increase PTEN expression leading to inhibition of Akt phosphorylation and 
induction of apoptosis [165, 166]. In contrast to this study, we did not observe a 
significant alteration in the PTEN/Akt signaling cascade in response to miRNA-214 
manipulation pointing towards a minor role of this pathway in the RT response of at 
least these NSCLC cells. Albeit it is not surprising that the same miRNA is regulating 
treatment response of different tumors by targeting different genes [167], there are a 
number of possible explanations to this discrepancy. First of all, we cannot rule out that 
miRNA-214 has mutation in part of the sequence binding to PTEN mRNA such 
mechanism has previously been shown for other miRNAs e.g. mutation in the sequence 
of miRNA-499 leads to failure of the miRNA to regulate mRNA targets in cardiac cells 
[168]. Another possible explanation is that PTEN mRNA is not expressed in sufficient 
amount to be targeted by miRNA-214 in our NSCLC cells. In support of this 
explanation is a report which demonstrated that at least a sub fraction of NSCLC 
tumors expresses low levels of PTEN [169]. Yet, another possibility is that PTEN is 
mutated rendering it insensitive to miRNA-214 regulation and in support for this is a 
study which demonstrated PTEN mutations in about 6% of NSCLC tumors [170]. 
DNA sequencing of both miRNA-214 and PTEN would reveal if any of these 
explanations are correct in this NSCLC system.  
Another predicted target of miRNA-214 was forkhead box protein O4 (FoxO4), a 
transcription factor which has been demonstrated to regulate different cellular processes 
including apoptosis and oxidative stress via the c-Jun N-terminal kinase (JNK) pathway 
[171]. We examined FoxO4 upon irradiation of the RS cells with forced overexpression 
of miRNA-214. Interestingly, we observed a reduction of apoptosis concomitant with 
increased phosphorylation of FoxO4 rather than a decrease which one would expect if 
miRNA-214 was directly targeting the FoxO4 mRNA. Our current hypothesis is that 
the increased FoxO4 phosphorylation is probably due to inhibitory effect of miRNA-
214 on upstream regulators of FoxO4. However, an inhibitory effect of FoxO4 
phosphorylation on apoptosis has been shown in endothelial progenitor cells via 
negative regulation of Bim [92]. Moreover, it has been demonstrated that FoxO4 
confers resistance to oxidative stress-induced apoptosis via p38MAPK pathway [172]. 
Given that we observed increased phosphorylation of p38MAPK upon miRNA-214 
overexpression and irradiation and that inhibiting p38MAPK activation re-sensitized 
the cells to RT, an effect of FoxO4 on p38MAPK is a plausible explanation that would 
be interesting to further examine. Furthermore, previous reports from our group also 
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support a role for p38MAPK in RT response as it was demonstrated that activation of 
this pathway via insulin-like growth factor 1 receptor (IGF-1R) enhances RT resistance 
in NSCLC [173]. However, how miRNA-214 regulates p38MAPK needs to be further 
explored as so far it has not been reported. Moreover, we observed alteration mainly in 
the phosphorylated form of p38MAPK whereas the total expression level was rather 
modest. This suggests that the regulation of p38MAPK by miRNA-214 most likely is 
indirect. Further studies are required to elucidate these possibilities.  
In conclusion, we show that knockdown of miRNA-214 sensitizes NSCLC cells to RT 
through induction of senescence with concomitant p27
Kip1 
up regulation. Moreover, we 
demonstrate that overexpression of miRNA-214 activates a FoxO4 and p38MAPK 
signaling pathway in response to RT in RS NSCLC cells thereby prevents RT-induced 
apoptosis. Modulation of different cell death/survival pathways by miRNA-214 in these 
NSCLC cells supports the concept that miRNA-214 is regulating multiple cellular 
processes and in a cell type-dependent manner. These findings are summarized in 
Figure 8.   
 
Figure 8. Mechanism of miRNA-214 regulation of RT response in NSCLC cells.  
 
 
 28 
4.2 Paper II 
miRNA-214 is related to invasiveness of human non-small cell lung cancer and 
directly regulates alpha protein kinase 2 expression 
Metastasis is considered the main etiological factor of poor prognosis of NSCLC as 
illustrated by shorter overall survival of the advanced stage of the disease as compared 
to early stages [174]. Therefore, finding biomarkers in the primary tumor which can 
predict metastatic spread or predict treatment response is urgently needed to sort out the 
NSCLC patients that should be given CT upfront as an adjuvant treatment. Interestingly 
miRNAs have previously been linked to metastasis of NSCLC for example 
overexpression of miRNA-143 has been shown to inhibit invasion and metastasis of 
NSCLC possibly via CD44v3 [175] and miRNA-335 has been shown to reduce 
metastasis of NSCLC cell lines via regulation of BCL2L2 and specificity protein 1 
(SP1) [176]. In paper I we identified miRNA-214 as a regulator of NSCLC RT 
response. Interestingly, a role for miRNA-214 in regulating metastasis of other human 
tumors has been reported i.e. in esophageal, cervical, hepatocellular, breast and gastric 
cancer where miRNA-214 inhibits metastasis by altering different signaling cascades 
[154, 177-182]. However, a role for miRNA-214 in driving NSCLC metastasis 
remained elusive. Therefore, we aimed to explore the role of miRNA-214 in the 
invasiveness of NSCLC in vitro, to identify putative targets involved in this process and 
to analyze their function in NSCLC clinical specimen as illustrated in Figure 9. 
We found that knockdown of miRNA-214 expression enhances invasiveness of 
NSCLC cells and vice versa, overexpression of the miRNA reduces invasive potential 
of the cells. Thus our results are in line with those reported in cervical, hepatocellular, 
breast and gastric cancer where miRNA-214 is described to inhibit metastasis [154, 
177-182]. However, our results are in contrast to what has been observed in metastatic 
melanoma where miRNA-214 was found to enhance metastasis [153]. These results 
illustrate that miRNA-214-induced regulation of metastasis is cell type-dependent and 
that in NSCLC cells miRNA-214 is a negative regulator of invasion capacity.  
Besides increasing the invasiveness of the cells, we found that miRNA-214 knockdown 
also reduced the proliferation rate of the NSCLC cells yet overexpression of the 
miRNA did not increase proliferation capacity which indicates that the effects of 
miRNA-214 are likely regulated by different pathways and in a cell type-dependent 
manner.  
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In order to identify putative genes involved in the miRNA-214 regulation of NSCLC 
invasion and metastasis we carried out gene expression profiling of NSCLC cells with 
ablated miRNA-214 expression. Results showed that blockade of miRNA-214 
expression in these NSCLC cells caused a direct or indirect up regulation of 297 and 
down regulation of 33 genes by at least 1.5-fold. As miRNAs are known to negatively 
regulate the expression of genes, the observed down regulation of 33 genes in the 
NSCLC cells with blocked miRNA-214 expression is likely due to indirect interaction 
of the miRNA-214 with upstream regulators of these genes. In order to search for 
reported miRNA-214 target genes among the observed gene expression alterations, we 
made use of Ingenuity miRNA target filter which identified 1360 genes to be potential 
targets of miRNA-214. After overlapping these potential targets with the 297 up 
regulated genes, a list of 18 common genes was found in our model system (Table 2).  
 
Table 2. List of genes up regulated after miRNA-214 ablation by at least 1.5-fold. 
Number Gene symbol Fold change 
1  EFCAB4B 2.0 
2  HDAC9 1.8 
3  ZBTB20 1.8 
4  TRAF1 1.7 
5  ALPK2* 1.6 
6  CDK6* 1.6 
7  TNFAIP3* 1.6 
8  CPEB4 1.6 
9  CYLD 1.6 
10  PDE5A 1.6 
11  MECOM 1.6 
12  MTMR7 1.6 
13  PAPPA* 1.5 
14  MYO1D 1.5 
15  NLGN1 1.5 
16  QTRTD1 1.5 
17  SPIRE1 1.5 
18  FAM122A 1.5 
 
* Metastasis-related targets of miRNA-214 in NSCLC. 
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To filter out metastasis-related targets of miRNA-214 in our data set, we made use of a 
previously published metastasis-associated gene signature identified in a metastatic 
mouse LC model with deleted liver kinase B1 (LKB1) and mutated KRAS [183]. We 
overlapped this signature with the list of 18 target genes of miRNA-214 in our model 
(Figure 9). Four genes were found to be in common with the metastasis signature. 
These were pregnancy-associated plasma protein A (PAPP-A), alpha protein kinase 2 
(ALPK2), cyclin-dependent kinase 6 (CDK6) and tumor necrosis factor, alpha-induced 
protein 3 (TNFAIP3).  
 
Figure 9. Schematic outline of the experimental setup (Project II).   
 
The four identified candidates were all validated to be altered at mRNA level using q-
RT-PCR. At protein level; however, PAPP-A, ALPK2 and CDK6 but not TNFAIP3 
were found to be regulated by miRNA-214 using a combination of different techniques 
(western blot, ELISA and immunofluorescence). With overexpression of miRNA-214, 
the level of these targets was reduced significantly, further supporting the results 
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achieved by the microarray technique. To test the direct or indirect regulation of these 
genes by miRNA-214, we used Ago2 immunoprecipitation as it has been shown that 
human miRNAs are directed towards their targets through Ago2 protein and that 
miRNA and their genes both can be recovered within this complex by such an approach 
[184]. Our results show that only ALPK2 is directly regulated by the miRNA-214 and 
the rest are likely indirect targets as they were not enriched in the Ago2 
immunoprecipitates. Hence, our results suggest that miRNA-214 regulates PAPP-A 
gene expression by influencing the expression of some of its upstream regulators e.g. 
transcription factors. In support for such hypothesis, we observed that besides PAPP-A, 
other members of metalloproteases were also up regulated after miRNA-214 
knockdown, such as matrix metalloproteinase 9 (MMP9) and leucyl/cystinyl 
aminopeptidase (LNPEP). Moreover, we identified that other regulatory factors of 
metalloproteases such as phospholipase D (PLD), interleukin 1 (IL1) and G-protein-
coupled receptor (GPCR) [185-187] were concomitantly up regulated after miRNA-
214 knockdown. This indicates that miRNA-214 is targeting upstream regulators of 
metalloproteases including PAPP-A. In conclusion, our data show that miRNA-214 is 
directly regulating the expression of ALPK2 while PAPP-A, CDK6 and TNFAIP3 are 
indirect targets of this miRNA. The possible role of miRNA-214 in regulating 
invasiveness of NSCLC is summarized in Figure 10.  
In order to understand the role of these targets in inducing metastasis and thus their 
correlation to survival of NSCLC patients, the protein expression level of PAPP-A, 
ALPK2, CDK6 and TNFAIP3 was examined through immunohistochemistry (IHC) of 
tissue microarrays (TMAs). For this purpose, a cohort of about 600 NSCLC specimens 
was used. We found that all these proteins were expressed in NSCLC clinical tumor 
specimen at moderate to high level as compared to normal tissue. However, there was 
no correlation between the expression level of these targets and the clinical records of 
metastasis or the OS of the NSCLC patients. There are at least two putative 
explanations to the lack of these associations. The first is presence of micro-metastasis 
in the clinically recorded cases as non-metastatic. The second explanation is technical 
and relates to the TMA construction and the heterogeneity of expression in different 
parts of the tumor specimen. As these proteins are involved in invasion, one can 
hypothesize that the expression level is higher in the invasive front of the tumor 
specimen. Since TMAs cover only a small piece of clinical tumor specimen and is   
taken from the core of the tumor, it is plausible that it does not cover the invasive front. 
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Hence our data call for extended analyses where the whole tissue or at least part of the 
tumor tissue including the invasive front is confined. For PAPP-A, the secreted form to 
the tumor environment rather that its intra tumor cell expression may play a role in 
induction of metastasis [188]. Therefore, it would be interesting to examine if the level 
of PAPP-A in the serum of these NSCLC patients is predictive of metastasis. 
Interestingly, high level of PAPP-A has been reported in serum of LC patients as 
compared to healthy controls albeit not in the context of metastasis [189].  
In conclusion, we show in this study, that miRNA-214 is playing a significant role in 
regulation of invasiveness of NSCLC in vitro and it is directly regulating ALPK2 but 
indirectly regulating PAPP-A, CDK6 and TNFAIP3. Furthermore, we show that 
NSCLC tumors express these proteins at moderate to high level but their significance in 
predicting metastasis needs to be further explored.  
 
Figure 10. Possible mechanism of miRNA-214-mediated regulation of invasiveness of 
NSCLC cells in vitro. The influence of PAPP-A on regulation of IGFBP-4/5 has been 
shown before and the latter is inducing invasiveness through activation of urokinase-
like plasminogen.  
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4.3 Paper III  
Gene expression profiling of cisplatin-refractory NSCLC residual clones reveals 
DKK1 as a potential novel driver of resistance 
Cisplatin is the mainstay CT used in the treatment of NSCLC; however, a large 
proportion  of the patients show intrinsic resistance and only about 20% of patients with 
advanced disease respond to the drug in the first line [190]. Therefore, identifying 
biomarkers predicting cisplatin responsiveness has clear clinical relevance so that 
unnecessary exposure of patients to the detrimental side effects of cisplatin can be 
minimized. Indeed biomarkers predicting response or prognosis of NSCLC patients 
treated with cisplatin have been investigated during the last decade. A number of 
potential predictive biomarkers have been described in NSCLC such as ERCC1, 
RRM1, BRCA1, RAP80 and KRAS [191-194]. Thus, low expression of ERCC1 has 
been shown to be associated with poor response to CT in patients with advanced 
NSCLC [193]. However, the results from other studies have shown that ERCC1 as well 
as the other biomarkers can only predict cisplatin- or combined CT response in a sub 
group of NSCLC patients i.e. those with certain tumor histology or mutations [191, 
192]. Sometimes the expression of more than one gene is necessary to predict the 
response to CT, for example the protein expression of BRCA1 per se failed to be 
associated with clinical outcome in NSCLC patients treated with cisplatin [195]. 
However, low mRNA expression of BRCA1 together with low RAP80 level was linked 
to a better outcome of advanced NSCLC patients treated with combined CT [192]. This 
suggests that multiple markers are likely required to be considered predictive to CT 
response. Therefore, identification of pathway aberrations rather than single genes will 
likely have greater potential to sort out CT responders from non-responders. For that 
purpose, we performed gene expression profiling of NSCLC cell clones surviving 
cisplatin treatment using a dose achievable in plasma [127]. We used only a single dose 
in order to identify the deregulated genes related to intrinsic resistance rather than 
acquired resistance property and performed the gene expression profiling of the 
surviving clones after 9 days. The results showed that these NSCLC had a 
heterogeneous response both in terms of survival and gene expression patterns. One 
may speculate that the heterogeneity of the clones in terms of gene expression is a 
result of survival of selective subgroups of cells with certain gene expression alterations 
rendering them resistant to treatment.  
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With a cutoff value of 1.5-fold up- or down regulation, we found that formin 1 
(FMN1), which has been shown to regulate the cell-cell junction [196], was the only 
gene which was down regulated in all of the three biological replicates. Cisplatin has 
been shown to disrupt cell-cell interaction followed by induction of apoptosis [197]. As 
FMN1 is regulating the cell-cell interaction and it is down regulated in the treatment 
resistant clones, cisplatin will be unable to disrupt the cellular junction and thus fail in 
inducing cell death. Further studies are required to prove this concept.  
Among the top de-regulated genes after cisplatin treatment, we found components of 
different DNA repair pathways which have been shown to enhance cisplatin resistance 
such as XRCC2 [198]. Apart from the DNA repair genes, we found a member of the 
Wnt signaling pathway, dickkopf-1 (DKK1), and a member of galectins, Lectin 
galactoside-binding soluble 9 (LGALS9), among the top up regulated genes in the 
cisplatin treatment surviving clones. LGALS9 is a member of galectins which have 
been shown to be linked to CT resistance [199, 200]. Thus overexpression of galectin-1 
has been shown to induce resistance of lung AC cells to cisplatin via interaction of 
Cox-2 and RAS and thereby activating p38MAPK, ERK and NFқB pathway [199]. In 
another study, the role of galectin-3 was found to be instrumental in pancreatic cancer 
cell resistance to gemcitabine-induced apoptosis [200]. These reports show the 
significance of galectins in CT resistance.  
In this study we identified DKK1, a negative regulator of Wnt signaling pathway, as a 
potential novel biomarker of cisplatin response in NSCLC. DKK1 has been shown to 
have a diverse oncogenic or tumor suppressive effect in different tumor types [201, 
202]. Thus down regulation of DKK1 has been shown to be associated with cisplatin 
resistance in head and neck cancer [201] and overexpression of DKK1 has been shown 
to sensitize glioma cells to the same agent [202]. Interestingly, in patients with NSCLC 
and esophageal cancer as compared to healthy controls, high serum level and high 
tumor expression of DKK1 have been observed, with the latter being associated with 
poor prognosis [203-205]. In order to prove a role of DKK1 as a driver of cisplatin 
resistance in NSCLC cells, we examined if siRNA-mediated suppression of DKK1 in 
these cells could sensitize for cisplatin treatment. Indeed, we could show that cells 
which had a reduced DKK1 expression become more sensitive to cisplatin as compared 
to the parental cells and had a reduced clonogenic capacity. Through Ingenuity 
Pathway Analysis (IPA) tool, we identified 16 upstream transcriptional regulators and 3 
downstream targets of DKK1. Among the upstream regulators of DKK1 we observed 
   35 
up regulation of TCF4, EZH2, DNAJB6 and HDAC2 in the cisplatin treatment 
surviving clones. Among the downstream targets of DKK1, we found CDKN1A, 
EPHB2 and GSK3B to be altered and we also showed that knockdown of DKK1 was 
associated with reduction in phosphorylation of GSK3B at serine 9 residue. 
Interestingly, an increased phosphorylation of GSK3B at serine 9 residue has been 
shown to confer resistance of ovarian cancer cells to cisplatin [73]. These data show 
that, DKK1 in part drives cisplatin resistance in NSCLC cells likely by regulating 
GSK3B signaling.   
In summary, we show that long term survival from cisplatin is associated with a 
heterogeneous survival response and gene expression pattern. Moreover, we found 
DKK1 as a potential novel marker for cisplatin resistance and a possible cisplatin 
sensitizing target.  
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5 GENERAL CONCLUSIONS AND FUTURE PERSPECTIVES 
The overall aims of this thesis were to find novel biomarkers for predicting response to 
conventional RT/CT and/or prognosis of LC patients as well as to identify novel 
sensitizing targets for such therapies. A systems biology approach was taken and gene 
and miRNA expression analyses in in vitro models of NSCLC were performed for this 
purpose. The future implications of our findings in the clinical setting and the 
challenges of these approaches are summarized below.  
 
Implications of miRNAs as targets for sensitization or as biomarkers of response 
to RT in NSCLC 
In paper I miRNA microarray on a panel of NSCLC and SCLC cell lines with 
different radiotherapy sensitivity identified only miRNA-214 to be associated with RT 
responsiveness across the NSCLC panel. However, a number of other miRNAs was 
found to have an expression level above noise and thereby might be of importance for 
RT response for each of these particular NSCLC cell lines. Connection of only one 
miRNA to RT phenotype may not be surprising as the NSCLC cell lines used were of 
various histological subtypes which have recently been shown to possess different 
miRNA expression patterns [206]. The differential expression of miRNAs in each 
NSCLC subtypes is possibly a result of activation of different signaling pathways in 
these tumors which require the compensatory amplification or deregulation of the 
miRNAs. Such co-evolution between expression of miRNAs and alterations on the 
DNA level could be achieved by mutations in the genes regulating the miRNA [207]. 
My conclusion after studying miRNAs in LC is therefore that it is more interesting to 
focus on the whole signaling network in which the miRNA is acting rather than just a 
single miRNA and thereby be able to understand the underlying driving machinery of 
each tumor subtype.  
Although findings in my thesis and work from others [208] illustrate that using 
miRNAs in the clinical practice is challenging, they may still have a role as biomarkers 
since miRNAs are stable in circulation and techniques are available to detect them [78]. 
However, even with this approach there are still certain difficulties. First, lack of a 
consistent internal control for normalization of miRNA expression level between 
different patient samples, although other studies have used equal serum volume as a 
normalization factor [78, 79]. Second, is difficulty in finding the upstream regulators of 
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miRNAs and the target genes regulated by miRNAs in a defined pathway which could 
be targeted therapeutically.  
 
p38MAPK as a RT sensitizing target for NSCLC  
From the RT point of view, an important finding of the thesis work is that miRNA-214 
alters p38MAPK signaling which influences RT response of NSCLC cells. A role of 
p38MAPK in RT response of NSCLC is also evident in previous studies from our 
group and others [126, 173, 209]. It has been shown that IR induces activation of 
p38MAPK pathway in NSCLC cells followed by induction of apoptotic signaling via 
the pro-apoptotic protein, Bak [126]. Furthermore, activation of p38MAPK pathway by 
IGF-1R was shown by our group to be associated with RR [173]. Another study in our 
group has shown that high linear energy transfer IR induces apoptosis in NSCLC cells 
by down regulating p38MAPK and in this way can circumvent conventional RT 
resistance [209]. Results from other groups have in contrast shown that IR induces 
apoptosis of NSCLC cells via p38MAPK activation which in turn leads to induction of 
mitochondrial apoptotic pathway and furthermore, inhibition of p38MAPK blocked the 
IR-induced apoptosis [210]. Interestingly, it has been shown that NSCLC tumors 
express activated p38MAPK as compared to normal lung tissue, albeit with no 
correlation to overall survival of the patients [211, 212]. It has further been shown in 
the same cohort that expression of ERCC1 is significantly associated with activation of 
p38MAPK [213]. Given our findings and these clinical reports in NSCLC, it might be 
worth testing p38MAPK inhibitors as RT sensitizers of NSCLC.  
 
Cisplatin resistance in NSCLC- from profiling of model systems to clinically 
relevant biomarkers 
Expression of ERCC1 and RRM1 has been shown to predict response of advanced 
NSCLC to cisplatin [30, 44] but still they are not used to guide treatment. Moreover, 
results show that these markers most likely will not be universal to all patients. In this 
context, the observation I made in paper III that cells surviving cisplatin treatment are 
heterogeneous in terms of gene expression highlights the necessity for individualized 
biomarkers of NSCLC rather than an approach where one marker fits all. It would 
therefore be interesting to identify biomarkers which predict response to treatment in 
selective patients based on gene expression analysis. We identified DKK1 as a potential 
novel biomarker of cisplatin resistance in NSCLC cell lines in vitro. It is thus 
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interesting to look for the protein expression of DKK1 in NSCLC tumor tissue before 
and after treatment to further clarify if DKK1 expression is indeed related to survival 
benefit of NSCLC patients to cisplatin.    
 
Concluding remarks  
miRNAs are negative regulators of a wide range of genes involved in dictating different 
cellular processes and thereby playing a master role in tumor development, progression 
and metastasis as well as in regulation of tumor cell response to treatment as illustrated 
in this thesis work. The use of miRNAs in the clinical setting is still not in practice as 
the translation from bench to bedside has been associated with certain challenges 
among them are the diversity of miRNA targets and heterogeneity of the tumors in 
miRNA expression. Yet to my understanding, these small RNA molecules have a 
promising future to be used as diagnostic, therapeutic or prognostic biomarkers or even 
to be evaluated as targets for new treatment regimens. The findings in this thesis add 
further information on the significance of miRNAs as future biomarkers in NSCLC.  
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هةر بةو . ى لةشيةكان خانة ئاسايي وةككاريطةريان تةنها لة سةر خانة شيَرثةنضةييةكان هةية نة
ة بؤ نمونة قذ كةمتر ضونكة  كاريطةري لاوةكي يان هؤيةشةوة بة باشتر دادةنريَت لة دةرمانة كيميايى يةكان
ةرنجة ئةوةية كة ئةو جؤرة ئةوةى ليَرة جى َى س. هتد...رشانةوة ,كةم بوونى بةرطرى لةش , رِووتانةوة
بؤية زؤربةى  . ةكان دؤزراونةتةوةتايبةتانة تا ئيَستا تةنها بؤ رِيَذةيةكى كةمى نةخؤشى ي نة دةرما
كة بةكاربيَت  دةكةنى زياتر دةرمان ن تا ئيَستا زؤر بة ضرِى كار لة سةر دؤزينةوةى ايةك تويَذينةوة زانستي
  .بؤ هةموو جؤرةكانى ئةو نةخؤشى ية
  . ى  تويَذينةوةى منة كة لة ضةند سالَى رِابردوودا ئةنجام دراون) 3( ئةو كتيَبةش بةرهةمى سىَ
ثيَش بردنى ضارةسةرى نةخؤشى شيَرثةنضةى  ضؤنيةتى بةرةو لة بريتين ئامانجى سةرةكى تويَذينةوةكانم
بؤ ئةم مةبةستةش .سنط بؤ بة دةستهيَنانى ئةنجامى  باشتر لة رِيَطةى دةرمانى كيميايى و رِيَطةى تيشك 
تويَذينةوةكانم بة كارهيَناوة بؤ دؤزينةوةى ثيَكهاتةى نةناسراوى ناو خانة شيَرثةنضةيى يةكان لة ريَطةى 
ئامانجيَكى ترى تويَذينةوةكانم بريتى يةلة ليَك .ؤر تازوة ثيَشكةوتوو بةكارهيَنانى تةكنيكى ز
جياكردنةوةى ئةو  نةخؤشانةى كة سوود وةردةطرن لةو نةخؤشانةى كة سوود وةرناطرن لة ضارةسةرى تيشك 
يان كيميايى لة رِيَطةى دياريكردنى جؤريَكى تايبةت لة ترشى ناووكى بةمةش كاريطةرى لاوةكى ضارةسةر لة 
  .   سةر نةخؤشةكة كةم دةبيَتةوة 
  : لة ئةنجامى ئةو تويَذينةوانة بؤمان دةركةوت كة 
هةية  كاريطةرى ) microRNA(  ى ترشى ناوةكى كة ثى َيان دةلَيَنيةكيَك لةو ثيَكهاتة نةناسراوانة -
ئةوا نةخؤشى  ثيَكهاتةية لة لةشى  مرؤظ لاببرىَبؤية ئةطةر ئةو  .لة سةر  تةشةنةكردنى شيَرثةنضةى سنط 
  .             يةكة تةشةنة ناكات و بةمةش ئةنجامى باشى نابيَت 
ئةو  كاريطةرى لة سةر  ضارةسةرى تيشكيش  هةية كة ئةوةش ئاماذةية بؤ ئةوةى  بوونى ئةو ثيَكهاتةية -
  .                             لة لةشى مرؤظ لاببرىَ يةثيَكهاتة
كة لة رِيَطةى تويَذينةوةى زانستى يةوة دةتوانين رِيَطة ضارةى نوىَ تر بؤ  ييدا بؤمان دةركةوتلة كؤتا
 نةخؤشى شيَرثةنضةى بدؤزينةوة لة رِيَطةى بةكارهيَنانى رِيَطةى نوى َبؤ ثشكنينى خانة شيَرثةنضةيى يةكان
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 ثوختةى تويَذينةوة :
لة ,ى لةشى مرؤظ خؤى ئاساييةكانناخانة بىَ كؤنترِؤل َلة هةنديَك لة ىيَكردنشيَرثةنضة بريتيية لة طةشةك
يان جى َبة  فةرمانةكانى خؤىةوةو ة جيَطةى خانة ئاسايى يةكان دةطرنيان ييئةنجامدا ئةو خانة نائاسا
نةى بة ؤذائةوا ناتوانيَت كاروبارى ر , بؤ نمونة ئةطةر نةخؤشيةكة تووشى ميَشكى مرؤظ ببيَت, جى َناكةن
لة كؤتاييدا ئةوةندة طةورة دةبي َكة دةبيَتة هؤى تةشةنةكردن و وةستاندنى فةرمانى  ئاسايى بةرِيَوةببات
بة شيَرثةنضة تا ئيَستا بة  هةر ضةندة هؤكارةكانى تووشبوون .مرؤظ  لةشى زؤربةى ئةندامة سةرةكييةكانى
هةنديَك هؤكارى دةرةكى وةك جطةرةكيَشان لة ئةنجامى ,بةلاَم بوونى هؤكارى بؤماوةيى , رِوونى نازانريَت 
  . تويَذينةوةى زانستى دةركةوتووة كة دةبيَتة هؤى تووشبوون بة شيَرثةنضة ضةندةها
  . كة تووشى مرؤظ دةبيَت دادةنريَت ة هةرة سةختترين نةخؤشيةكانل بة يةكيَكنةخؤشى شيَرثةنضة 
  .شندةترين جؤرى شيَرثةنضة دةذميَردريَت لة هةموو جيهان بة باوترين و كو) سنط( سى يةكان شيَرثةنضةى
يةك مليؤن و شةش ) 111011600(نزيكةى  رِيَذةى تووشبووان بة نةخؤشى شيَرثةنضةى سنط لة سالَيَكدا بة
يةك مليؤن و سى َسةد  )111011300(وة لة هةمان كاتدا بة هؤكارى مردنى ,دةخةمليَنريَت كةس سةد هةزار
هةر ضةندة ليَكؤلَينةوةكان وا ثيشان دةدةن كة نزيكةى  . نريَت لة هةموو جيهان  لة سالَيَكداكةس دادة هةزار
ى تووشبوان بة شيَرثةنضةى سنط % 10تووشى شيَرثةنضةى سى يةكان دةبن بةلاَم   ى جطةرةكيَشةكان %10
  . جطةرةكيَشن يان جطةرةيان كيَشاوة لة رابردوودا
نةشتةرطةرى  رثةنضةى سنط بريتي ية لة لابردنى طرى َيةكة لة رِيَطةىى شيَبة شيَوةيةكى طشتى ضارةسةر
ة و لةو ولة زؤربةى كاتةكان نةخؤشي يةكة تةشةنةى كردو بةلاَم .تةشةنةى نةكردبى َنةخؤشى يةكة ئةطةر 
  .دةبيَت ) اًشعة(تيشك ليَدانى  حالَةتةشدا ضارةسةرى لة ريَطةى دةرمانى كيميايى يان لة رِيَطةى
لة ئةنجامى ضةندين تويَذينةوةى زانستى دا هةنديَك دةرمانى تازة  سالَى رابردوودا) 10(دة لة  
دؤزراونةتةوة كة جياوازن لة دةرمانة كيميايى ية باوةكان كة ثي َيان نالَيَن دةرمانى كيميايى بةلَكو دةرمانى 
  تازانة ئةوةية كة نةيةكيَك لة تايبةتمةندي يةكانى ئةو دةرما . )Taygoed theoapy(  تايبةتن
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